1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Iolyx Therapeutics Inc. has 1 pending office action handled by 1 distinct examiner in 0 distinct art units. The pending matter is assigned to CHANDRAKUMAR, NIZAL S, who is also the busiest examiner with 1 pending matter.
The concentrated assignment gives counsel a single examiner relationship to manage. A focused response can address the immediate action without needing to reconcile positions across multiple art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18897425 | METHODS FOR OPHTHALMIC DELIVERY OF ROFLUMILAST | CHANDRAKUMAR, NIZAL S | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18897425 | METHODS FOR OPHTHALMIC DELIVERY OF ROFLUMILAST | CHANDRAKUMAR, NIZAL S | — | §103Other | Non-Final OA | — | Pending | Sep 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIolyx Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Nizal S Chandrakumar has the most, with 1 of Iolyx Therapeutics Inc.'s pending office actions.
